Search results
Added:
1 month ago
In the latest episode of Arrhythmia Academy’s Journal Club, Prof Serge Boveda (Clinic Pasteur, Toulouse, FR) is joined by Prof José Luis Merino (La Paz University Hospital, Madrid, ES) to discuss the EHRA Practical Compendium on Anti-Arrhythmic Drugs (AADs) and its relevance to everyday electrophysiology practice.The discussion highlights why AADs remain central to arrhythmia management despite…
View more
AV Junction Ablation and Device Therapy in AF
Added:
2 months ago
Review Article
Added:
1 month ago
Source:
Radcliffe Cardiology
A prespecified substudy of the VANISH2 trial suggests first-line catheter ablation is superior to sotalol for reducing arrhythmia events in eligible patients with ischaemic cardiomyopathy and ventricular tachycardia (VT).¹ In patients ineligible for sotalol, ablation showed comparable efficacy to amiodarone but with a markedly better long-term safety profile.MethodologyThe VANISH2 (Ventricular…
View more
Start date:
Oct 23, 2024
This session covers the latest data on transvenous and subcutaneous ICD devices, focusing on shared decision-making and their practical applications in preventing sudden cardiac death. Moderated by Dr Blandine Mondésert (Montreal Heart Institute and University of Montreal, CA) and Dr Ulrika Birgersdotter-Green (University of California San Diego, US), this webinar delves into the long-term…
View more
Real-world Outcomes of AVNA: 10-year Results
Added:
1 month ago
Original Research
Drug-induced AF
Added:
1 year ago
Review Article
Added:
2 months ago
Added:
1 month ago
Source:
Arrhythmia Academy
A new substudy of the VANISH2 trial suggests that for patients with prior myocardial infarction and ventricular tachycardia (VT) who are eligible for sotalol, catheter ablation leads to better outcomes than antiarrhythmic drug (AAD) therapy.¹ For patients eligible only for amiodarone, efficacy was comparable, but amiodarone was associated with a significant increase in adverse events…
View more
Added:
11 months ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire…
View more
Added:
1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study…
View more